Exhibit (a)(2)Cotherix Inc • December 8th, 2006 • Biological products, (no disgnostic substances)
We are pleased to inform you that on November 19, 2006, CoTherix, Inc. (“CoTherix”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Actelion US Holding Company (“Actelion US”) and Curl Acquisition Subsidiary, Inc. (the “Purchaser”), a wholly owned subsidiary of Actelion US. As provided in the Merger Agreement, the Purchaser today commenced a tender offer (the “Offer”) to purchase all outstanding shares of CoTherix’s common stock (the “Shares”) at a price of $13.50 per share, in cash, without interest thereon (the “Offer Price”). The Offer is subject to the terms and conditions in the Purchaser’s Offer to Purchase and the related Letter of Transmittal that are included in the Purchaser’s offering materials. As provided in the Merger Agreement and subject to the satisfaction or waiver of certain conditions, the Offer will be followed by a merger (the “Merger”) of the Purchaser with and into CoTherix, and all Shares not purchased in the Offer (other than Shares
